Werewolf Therapeutics announces strategic alternatives review; Q4 2025 net loss $8.4M

Werewolf Therapeutics, Inc.

Engaged Piper Sandler as exclusive financial advisor to explore strategic alternatives including sale, merger, or asset sale.
Cash and equivalents of $57.1M as of Dec 31, 2025; expected to fund operations into Q4 2026.
Q4 2025 net loss $8.4M vs $20.4M in Q4 2024; R&D expenses $6.9M vs $15.7M.
Full year 2025 net loss $60.8M vs $70.5M; R&D expenses $44.8M vs $56.4M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Werewolf Therapeutics, Inc. reported full year ended December 31, 2025 results: net income Net loss was $60.8 million.

Period: full year ended December 31, 2025
Net income: Net loss was $60.8 million
Result: reported results

Exact text from the filing

Net loss was $60.8 million for the full year 2025

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Werewolf Therapeutics, Inc. reported quarter ended December 31, 2025 results: net income Net loss was $8.4 million.

Period: quarter ended December 31, 2025
Net income: Net loss was $8.4 million
Result: reported results

Exact text from the filing

Net loss was $8.4 million for the fourth quarter of 2025

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-26-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.